Wednesday, July 8, 2026

Drug profile · INN

docetaxel

docetaxel (DOCETAXEL ACCORD) is a tubulin inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01CD02
US status approved
Patents linked 20
Pipeline programs 120
News articles 1
Drug details — docetaxel
US status
approved
Class
Antineoplastic and immunomodulating agents (L01)
Route
INJECTION
Patents
20
Programs
120
Data quality
0.89

Quick answer

docetaxel (DOCETAXEL ACCORD) is a tubulin inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN docetaxel
Brand DOCETAXEL ACCORD
Mechanism Tubulin inhibitor
Target Tubulin
Therapeutic class Antineoplastic and immunomodulating agents (L01)
Route INJECTION
Formulation INJECTABLE
ATC code L01CD02

Mechanism of action

Tubulin inhibitor

Primary target: Tubulin

Approval history

Authority Status Date
FDA approved
EMA approved
TGA approved
NMPA clinical trials

Recent coverage

Pipeline programs

  1. 000434 Phase 3 · Ferring Pharmaceuticals · High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-mu
  2. 20190009 Phase 3 · Amgen · Previously treated locally advanced and unresectable or meta
  3. 2020HXFH037 Phase 3 · Chinese Academy of · Nasopharyngeal Carcinoma
  4. 2022-009 Phase 3 · Ningbo Cancer Hospital · metastatic breast cancer
  5. 20230239 Phase 3 · Amgen · Metastatic castration-resistant prostate cancer (mCRPC)
  6. 213410 Phase 3 · GSK Glaxo Smith · Lung Cancer, Non-Small Cell
  7. 42756493BLC3001 Phase 3 · Janssen-Cilag International N.V · Advanced Urothelial Cancer
  8. 5-Fu/epirubicin/CTX following Docetaxel Phase 3 · Chinese Academy of · Breast Cancer

Related & competitor drugs

  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)
  1. US 12258366

    Bicyclic heteroaryl compounds and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 11987590

    Compounds that participate in cooperative binding and uses thereof

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 11607407

    Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use

    Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 11512128

    VEGF/DLL4 binding agents and uses thereof

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11434204

    Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11234967

    Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11168102

    Bicyclic heteroaryl compounds and uses thereof

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11059830

    Compounds that participate in cooperative binding and uses thereof

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 10995071

    Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

    Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 10948495

    Methods and reagents for analyzing protein-protein interfaces

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10934260

    Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

    Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10624887

    Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14,-diol

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10533016

    Compounds that participate in cooperative binding and uses thereof

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10466249

    Methods and reagents for analyzing protein-protein interfaces

    Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10080720

    Pharmaceutical composition containing docetaxel

    Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 9364430

    Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 2013178639

    CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAME

    Expires Wed Jul 06 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 8481511

    Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process

    Expires Mon Jul 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 8329744

    Methods of preventing the serotonin syndrome and compositions for use thereof

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 8044093

    Pharmaceutical compositions comprising docetaxel and methods for preparation thereof

    Expires Mon Oct 20 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is docetaxel?

docetaxel (DOCETAXEL ACCORD) is a tubulin inhibitor. Associated with Accord Healthcare Pty.. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for docetaxel?

DOCETAXEL ACCORD is a marketed brand name for docetaxel. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of docetaxel?

docetaxel has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.